Table 1:
Patient characteristics of the PS-matched SZC and no K+ binder cohorts at baseline.
| USA | Japan | Spain | ||||
|---|---|---|---|---|---|---|
| Characteristics | SZC (n = 565) | No K+ binder (n = 2068) | SZC (n = 776) | No K+ binder (n = 2629) | SZC (n = 56) | No K+ binder (n = 203) |
| Age, years, mean ± SD | 72.1 ± 10.2 | 72.4 ± 9.8 | 75.8 ± 10.9 | 76.2 ± 10.3 | 71.8 ± 8.3 | 69.4 ± 11.1 |
| Sex (female), n (%) | 249 (44.1) | 923 (44.6) | 258 (33.3) | 886 (33.7) | 23 (41.1) | 84 (41.4) |
| HK severity at index, n (%)a,b | ||||||
| Mild | 30 (28.0) | 114 (27.6) | 21 (28.0) | 69 (40.8) | 15 (26.8) | 55 (27.1) |
| Moderate | 44 (41.1) | 160 (38.7) | 30 (40.0) | 57 (33.7) | 31 (55.4) | 116 (57.1) |
| Severe | 33 (30.8) | 139 (33.7) | 24 (32.0) | 43 (25.4) | 10 (17.9) | 32 (15.8) |
| Missing | 458 (81.1) | 1655 (80.0) | 701 (90.3) | 2460 (93.6) | 0 (0) | 0 (0) |
| CKD, n (%) | 545 (96.5) | 1997 (96.6) | 631 (81.3) | 2239 (85.2) | 42 (75.0) | 154 (75.9) |
| CKD stage, n (%)a | ||||||
| CKD3 | 247 (47.2) | 892 (46.2) | 40 (18.7) | 108 (15.2) | 25 (61.0) | 103 (74.1) |
| CKD4 | 217 (41.5) | 820 (42.5) | 75 (35.0) | 270 (38.0) | 13 (31.7) | 33 (23.7) |
| CKD5 | 59 (11.3) | 219 (11.3) | 99 (46.3) | 333 (46.8) | 3 (7.3) | 3 (2.2) |
| Missing | 27 (4.8) | 88 (4.3) | 417 (53.7) | 1528 (58.1) | 1 (1.8) | 15 (7.4) |
| Heart failure, n (%) | 196 (34.7) | 708 (34.2) | 572 (73.7) | 1960 (74.6) | 18 (32.1) | 70 (34.5) |
| Diabetes, n (%) | 446 (78.9) | 1657 (80.1) | 725 (93.4) | 2467 (93.8) | 34 (60.7) | 123 (60.6) |
| Recurrent or new-onset hyperkalaemia, n (%) | ||||||
| New-onset | 43 (7.6) | 153 (7.4) | 148 (19.1) | 280 (10.7) | 3 (5.4) | 2 (1.0) |
| Recurrent | 522 (92.4) | 1915 (92.6) | 628 (80.9) | 2349 (89.4) | 53 (94.6) | 201 (99.0) |
| K+ binder prescription in the 12 months before index, n (%) | 302 (53.5) | 979 (47.3) | 572 (73.7) | 2151 (81.8) | 30 (53.6) | 54 (26.6) |
a
Proportions are calculated excluding missing data.
b
Mild, moderate and severe hyperkalaemia equate to K+ values of 5–5.49, 5.5–5.99 and ≥6.0 mmol/l, respectively.